Clinical and Translational Science Collaborative of Cleveland
克利夫兰临床与转化科学合作组织
基本信息
- 批准号:10152707
- 负责人:
- 金额:$ 593.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-15 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseBasic ScienceBiotechnologyCitiesClinicClinicalClinical InvestigatorClinical ResearchClinical SciencesClinical TrialsCollaborationsCommon ColdCommunitiesCountryDisadvantagedEnsureEnvironmentFacultyFoundationsFundingGenetic DiseasesGoalsGovernment AgenciesGrantHealthHealth BenefitHealth systemHealthcareHospitalsHumanIncubatedIndividualInfant MortalityInformaticsInstitutionKnowledgeLaboratoriesLeadershipLife ExpectancyLocationLongevityMalignant NeoplasmsMedical centerMethodsModelingMovementNational Research Service AwardsNeighborhoodsNeurodegenerative DisordersPatientsPersonal SatisfactionPopulationPositioning AttributePreparationProcessProgram DevelopmentRecommendationResearchResearch MethodologyResearch SupportResearch TrainingResourcesScienceSiteSolidSpecial PopulationSystemTNFSF15 geneTestingTimeTrainingTraining SupportTranslational ResearchTranslationsUnderserved PopulationUnited States Department of Veterans AffairsUnited States National Institutes of HealthUniversitiesUniversity HospitalsVisionbasecareer developmentcatalystclinical research sitecollaborative environmentdesignflexibilityhealth disparityimprovedinner cityinnovationmembermulti-site trialnext generationnovel therapeuticsoperationprogramsprototyperesearch clinical testingresearch facilitystatisticssuburbsuccesstranslational scientist
项目摘要
Clinical and translational (C/T) research is essential to bring the discoveries of biomedical science to benefit the
health and well-being of our nation. The Clinical and Translational Science Collaborative (CTSC) of Cleveland,
a collaborative among Case Western Reserve University (CWRU) and its affiliated hospital systems, the
Cleveland Clinic (CC), MetroHealth (MH), University Hospitals (UH), and the Louis Stokes Veterans
Administration Medical Center (VA), aspires to be a catalyst for high quality C/T research both locally and
nationally. The CTSC operates as a fully integrated cooperative, collaborative, and confluent research
environment that supports all aspects of clinical and translational science, enabling full access by university
faculty at all partner institutions to all CTSC-associated potential collaborators and research resources. It has
positioned itself to assume leadership in disseminating best practices and promoting multi-site clinical research.
It now seeks funding to support the development of program support required to advance the goals set forth by
the 2013 recommendations for the CTSA Program by the IOM (now NAM). The CTSC of Cleveland has created
a solid foundation on which to build from, to utilize the power of this collaborative to ensure rigorous and
innovative training of the C/T/ workforce, to accelerate the translation of discoveries to patients, to improve the
health of Cleveland, and to provide scalable models for other locations throughout the nation. To realize its
vision, the CTSC of Cleveland proposes to engage all C/T science stakeholders, the workforce, patients and
community members to collaborate locally, regionally, and nationally, to 1) advance human health, 2) develop
and cultivate the current and next generation C/T research workforce, with special focus on preparation for team
science and increasing the diversity of the workforce, 3) promote integration of our translational processes from
discovery through clinical trials, of our community throughout the research enterprise, and of special and
underserved populations into C/T research across the lifespan, 4) increase the quality and efficiency of C/T
research, particularly multi-site trials, through innovative methods and processes and strong collaboration among
CTSC Hubs, and 5) provide innovative informatics to support the training and research environment both within
the CTSC and nationally. The CTSC has designed an Administrative Core, six C/T research components:
Informatics, Community and Collaboration, Translational Endeavors, Research Methods, Hub Research
Capacity, and Network Capacity; and two formal C/T training cores: Institutional Career Development Core
(KL2), and the NRSA Training Core (TL1) to accomplish its goals. Commitment to collaboration and innovation
in C/T research remain top priorities as the CTSC implements its aims and builds the new iteration of the Clinical
and Translational Science Collaborative of Cleveland.
临床和转化(C/T)研究是使生物医学科学的发现造福于
我们国家的健康和福祉。克利夫兰临床与转化科学合作组织(CTSC),
凯斯西部储备大学(CWRU)及其附属医院系统之间的合作,
克利夫兰诊所(CC)、MetroHealth(MH)、大学医院(UH)和Louis Stokes退伍军人
行政医学中心(VA),渴望成为高质量的本地和
全国范围内。CTSC以完全整合的合作、协作和融合研究的方式运作
支持临床和转化科学的方方面面的环境,使大学能够完全访问
所有伙伴机构的教师向所有与CTSC相关的潜在合作者和研究资源提供信息。它有
将自己定位为在传播最佳实践和促进多地点临床研究方面发挥领导作用。
它现在正在寻求资金,以支持发展所需的方案支持,以推进以下目标
国际移民组织(现为不结盟运动)2013年对CTSA计划的建议。克利夫兰的CTSC创造了
坚实的基础,在此基础上构建并利用此协作的力量,以确保
对C/T/工作人员进行创新培训,以加快将发现转化为患者,改善
克利夫兰的健康,并为全国各地的其他地点提供可扩展的模型。实现ITS
VISION,克利夫兰的CTSC建议让所有C/T科学利益相关者、员工、患者和
社区成员在地方、区域和国家范围内合作,1)促进人类健康,2)发展
培养当前和下一代C/T研究队伍,特别注重为团队做准备
科学和增加劳动力的多样性,3)促进我们的翻译流程从
通过临床试验,我们的社区在整个研究企业中的发现,以及特殊和
在整个生命周期内将服务不足的人群纳入C/T研究,4)提高C/T的质量和效率
研究,特别是多点试验,通过创新的方法和程序以及
CTSC中心,以及5)提供创新的信息学,以支持培训和研究环境
CTSC和全国范围内。CTSC设计了一个行政核心,包括六个C/T研究组成部分:
信息学、社区与协作、翻译努力、研究方法、中心研究
能力和网络能力;以及两个正式的C/T培训核心:机构职业发展核心
(KL2)和NRSA培训核心(TL1),以实现其目标。致力于协作和创新
随着CTSC实现其目标并建立新的临床迭代,C/T研究仍然是首要任务
和克利夫兰翻译科学合作组织。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GRACE A MCCOMSEY其他文献
GRACE A MCCOMSEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GRACE A MCCOMSEY', 18)}}的其他基金
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)
北俄亥俄州临床和转化科学合作组织,促进健康公平的联系 (CLE Health)
- 批准号:
10704417 - 财政年份:2023
- 资助金额:
$ 593.37万 - 项目类别:
Clinical and Translational Science Collaborative of Cleveland
克利夫兰临床与转化科学合作组织
- 批准号:
10400700 - 财政年份:2018
- 资助金额:
$ 593.37万 - 项目类别:
Incremental effect of smoking on HIV immune activation and cardiac health
吸烟对艾滋病毒免疫激活和心脏健康的增量影响
- 批准号:
8915891 - 财政年份:2014
- 资助金额:
$ 593.37万 - 项目类别:
Vitamin D, drug metabolism, and cardiovascular complications in pediatric HIV
儿科 HIV 患者的维生素 D、药物代谢和心血管并发症
- 批准号:
8196123 - 财政年份:2011
- 资助金额:
$ 593.37万 - 项目类别:
Vitamin D, drug metabolism, and cardiovascular complications in pediatric HIV
儿科 HIV 患者的维生素 D、药物代谢和心血管并发症
- 批准号:
8511762 - 财政年份:2011
- 资助金额:
$ 593.37万 - 项目类别:
Vitamin D, drug metabolism, and cardiovascular complications in pediatric HIV
儿科 HIV 患者的维生素 D、药物代谢和心血管并发症
- 批准号:
8898162 - 财政年份:2011
- 资助金额:
$ 593.37万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 593.37万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 593.37万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 593.37万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 593.37万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 593.37万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 593.37万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 593.37万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 593.37万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 593.37万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 593.37万 - 项目类别:














{{item.name}}会员




